New York, United States , March 30, 2023 (GLOBE NEWSWIRE) -- The Global Nasopharyngeal Carcinoma Market Size is projected to reach multimillion USD by 2030, in comparison to 2021, at a CAGR of 5.6 ...

Among 6,319 patients, the most common primary sites were nasopharynx (33%), oral cavity (23%), oropharynx (17%), larynx (15%), and hypopharynx (8%). An increase in human papillomavirus–related ...

“Following our recent EU approval of TEVIMBRA for extensive-stage small cell lung cancer, this new authorization in nasopharyngeal carcinoma reflects strong momentum in broadening access to our ...

Key Takeaways Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the ...

People with locally advanced head and neck squamous cell carcinoma (HNSCC) now have a new treatment option that could extend their lives with fewer side effects. The U.S. Food and Drug Administration ...

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination treatment for nasopharyngeal cancer. The company formerly known as BeiGene ...

In a phase 3, randomized trial, we enrolled patients with local or regional cutaneous squamous-cell carcinoma, after surgical resection and postoperative radiotherapy, at high risk for recurrence ...